Eligible patients were randomized to eribulin mesylate 2.0 mg/m ( 2 ) on day 1 with erlotinib 150 mg on days 2-16 ( 21-day regimen ) or eribulin mesylate 1.4 mg/m ( 2 ) on days 1 and 8 with erlotinib 150 mg on days 15-28 ( 28-day regimen ) .